MA25403A1 - Ligandes de recepteur de melanocortine - Google Patents
Ligandes de recepteur de melanocortineInfo
- Publication number
- MA25403A1 MA25403A1 MA26340A MA26340A MA25403A1 MA 25403 A1 MA25403 A1 MA 25403A1 MA 26340 A MA26340 A MA 26340A MA 26340 A MA26340 A MA 26340A MA 25403 A1 MA25403 A1 MA 25403A1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor ligands
- melanocortine
- melanocortine receptor
- ligands
- receptor
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12667399P | 1999-03-29 | 1999-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA25403A1 true MA25403A1 (fr) | 2002-04-01 |
Family
ID=22426131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA26340A MA25403A1 (fr) | 1999-03-29 | 2001-09-26 | Ligandes de recepteur de melanocortine |
Country Status (34)
Country | Link |
---|---|
US (2) | US6613874B1 (fr) |
EP (1) | EP1165613B1 (fr) |
JP (1) | JP2002542159A (fr) |
KR (2) | KR100558131B1 (fr) |
CN (1) | CN1249086C (fr) |
AR (1) | AR023201A1 (fr) |
AT (1) | ATE393783T1 (fr) |
AU (1) | AU763510B2 (fr) |
BR (1) | BR0009497A (fr) |
CA (1) | CA2368431C (fr) |
CO (1) | CO5170531A1 (fr) |
CZ (1) | CZ20013407A3 (fr) |
DE (1) | DE60038734T2 (fr) |
DK (1) | DK1165613T3 (fr) |
ES (1) | ES2304345T3 (fr) |
HK (1) | HK1044954B (fr) |
HU (1) | HUP0202203A3 (fr) |
ID (1) | ID30262A (fr) |
IL (1) | IL145406A0 (fr) |
MA (1) | MA25403A1 (fr) |
MX (1) | MXPA01009881A (fr) |
MY (1) | MY126585A (fr) |
NO (1) | NO20014568L (fr) |
NZ (1) | NZ514141A (fr) |
PE (1) | PE20001641A1 (fr) |
PL (1) | PL350095A1 (fr) |
PT (1) | PT1165613E (fr) |
RU (1) | RU2213098C2 (fr) |
SA (1) | SA00210192B1 (fr) |
SK (1) | SK13082001A3 (fr) |
TR (1) | TR200102765T2 (fr) |
TW (1) | TWI250990B (fr) |
WO (1) | WO2000058361A1 (fr) |
ZA (1) | ZA200107411B (fr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064091A2 (fr) | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Metallopeptides de melanocortine pour le traitement de dysfonctions sexuelles |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
AU766191B2 (en) | 1999-06-04 | 2003-10-09 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US6693165B2 (en) | 2000-01-18 | 2004-02-17 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
PL366630A1 (en) | 2000-08-30 | 2005-02-07 | F.Hoffmann-La Roche Ag | Selective cyclic peptides |
CN1571796A (zh) * | 2000-09-27 | 2005-01-26 | 宝洁公司 | 黑皮素受体配体 |
US7342089B2 (en) * | 2001-07-11 | 2008-03-11 | Palatin Technologies, Inc. | Cyclic peptides for treatment for cachexia |
JP2004534851A (ja) | 2001-07-11 | 2004-11-18 | パラチン テクノロジーズ インク. | メラノコルチン受容体に特異的な線状および環状ペプチド |
US7345144B2 (en) * | 2001-07-11 | 2008-03-18 | Palatin Technologies, Inc. | Cyclic peptides for treatment of cachexia |
US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
US7034004B2 (en) * | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
JP2006527772A (ja) * | 2003-06-19 | 2006-12-07 | イーライ リリー アンド カンパニー | メラノコルチン3受容体(mc3r)作用薬ペプチドの用途 |
MXPA05013951A (es) * | 2003-06-19 | 2006-02-24 | Lilly Co Eli | Agonsita del receptor de la melanocortina 4 (mc4) y sus usos. |
EP1670815A2 (fr) * | 2003-09-30 | 2006-06-21 | Novo Nordisk A/S | Nouveaux agonistes du recepteur de la melanocortine |
AU2015201062B2 (en) * | 2003-11-05 | 2017-03-09 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
EP2332968B1 (fr) * | 2003-11-05 | 2016-05-04 | Dana-Farber Cancer Institute, Inc. | Peptides alpha-hélicaux pour l'activation ou l'inhibition de la mort cellulaire |
CA2552043A1 (fr) | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Conjugaison de peptides induite par la transglutaminase |
US6974187B2 (en) * | 2004-01-28 | 2005-12-13 | Tachi-S Co., Ltd. | Vehicle seat structure |
CA2557739A1 (fr) * | 2004-03-29 | 2005-11-03 | Eli Lilly And Company | Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue |
WO2006041769A2 (fr) * | 2004-10-05 | 2006-04-20 | Merck & Co., Inc. | Procedes de traitement d'un abus d'une substance d'une addiction a cette substance |
WO2006060873A1 (fr) * | 2004-12-09 | 2006-06-15 | Prince Henry's Institute Of Medical Research | Procede de restauration de la fonction reproductrice |
WO2006073771A2 (fr) * | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol |
WO2006073772A1 (fr) * | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Peptides agonistes de mc4r ou de mc3r lies a un polyethyleneglycol |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US7754691B1 (en) | 2005-07-07 | 2010-07-13 | Palatin Technologies, Inc. | Linear melanocortin receptor-specific peptides for cachexia |
KR101232201B1 (ko) | 2005-07-08 | 2013-02-12 | 입센 파마 에스.에이.에스 | 멜라노코르틴 수용체 리간드 |
JP2009500426A (ja) * | 2005-07-08 | 2009-01-08 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | メラノコルチン受容体のリガンド |
EP1968995A1 (fr) * | 2005-12-30 | 2008-09-17 | F. Hoffmann-la Roche AG | Procede de synthese de peptides contenant arginine |
EP2035373B1 (fr) | 2006-06-09 | 2011-05-04 | Action Pharma A/S | Dérivés de phényl pyrrole aminoguanidine |
US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
CA2686827C (fr) * | 2006-12-14 | 2014-09-16 | Aileron Therapeutics, Inc. | Systemes de macrocyclisation bis-sulfhydryle |
EP2118123B1 (fr) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Peptides p53 stabilises et utilisations de ceux-ci |
EP3301108A1 (fr) | 2007-02-23 | 2018-04-04 | Aileron Therapeutics, Inc. | Systèmes macrocycliques de triazole |
WO2008121767A2 (fr) | 2007-03-28 | 2008-10-09 | President And Fellows Of Harvard College | Polypeptides cousus |
TWI364290B (en) | 2007-05-25 | 2012-05-21 | Ipsen Pharma Sas | Melanocortin receptor ligands modifled with hydantoin |
KR20100126361A (ko) | 2008-02-08 | 2010-12-01 | 에일러론 테라퓨틱스 인코포레이티드 | 치료용 펩티드유사 거대고리 |
US20110144303A1 (en) * | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
US20090326192A1 (en) * | 2008-04-08 | 2009-12-31 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
AU2009257631B2 (en) | 2008-06-09 | 2014-07-24 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
AR072072A1 (es) * | 2008-06-09 | 2010-08-04 | Palatin Technologies Inc | Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669 |
WO2010011313A2 (fr) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligature de polypeptides agrafés |
CA2737921C (fr) | 2008-09-22 | 2019-01-15 | Aileron Therapeutics, Inc. | Methodes de preparation de compositions de macrocycles peptidomimetiques alpha-helicoidaux purifies ayant des taux faibles de ppm de metal |
BRPI1006139A2 (pt) | 2009-01-14 | 2017-05-30 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
MX2011013117A (es) | 2009-06-08 | 2012-05-23 | Palatin Technologies Inc | Peptidos especificos del receptor de melanocortina. |
EP2440572B1 (fr) | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Peptides spécifiques des récepteurs aux mélanocortines à pont lactame |
US9163330B2 (en) | 2009-07-13 | 2015-10-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
EP2480565A4 (fr) | 2009-09-22 | 2014-01-01 | Aileron Therapeutics Inc | Macrocycles peptidomimétiques |
US20120226018A1 (en) * | 2009-11-16 | 2012-09-06 | Ipsen Pharma, S.A.S. | Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 |
CA2781405A1 (fr) | 2009-11-23 | 2011-05-26 | Palatin Technologies, Inc. | Peptides lineaires specifiques du recepteur de la melanocortine-1 |
WO2011063366A1 (fr) | 2009-11-23 | 2011-05-26 | Palatin Technologies, Inc. | Peptides cycliques spécifiques du récepteur de la mélanocortine-1 |
CN101824415A (zh) * | 2010-03-31 | 2010-09-08 | 华东师范大学 | 黑素皮质1型受体基因的snp及其应用 |
WO2012021876A2 (fr) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques |
WO2012040459A2 (fr) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Peptides de ciblage de la béta-caténine et leurs utilisations |
CA2825098C (fr) | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine et derives de pyrazolopyrimidine en tant que modulateurs du recepteur de la melanocortine-4 |
WO2012174423A1 (fr) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Polypeptides stabilisés comme régulateurs de fonction gtpase rab |
AU2012326026B2 (en) | 2011-10-18 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
PT2920197T (pt) | 2012-09-26 | 2021-06-11 | Harvard College | Péptidos agrafados com bloqueio de prolina e suas utilizações |
SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
SG10201913593WA (en) | 2013-03-13 | 2020-02-27 | Harvard College | Stapled and stitched polypeptides and uses thereof |
CA2915354A1 (fr) | 2013-06-14 | 2014-12-18 | President And Fellows Of Harvard College | Modulateurs stabilises du recepteur de l'insuline polypeptidique |
WO2015179635A2 (fr) | 2014-05-21 | 2015-11-26 | President And Fellows Of Harvard College | Peptides inhibiteurs de ras et leurs utilisations |
CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
WO2016049359A1 (fr) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et leurs utilisations |
AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
CN110681362B (zh) * | 2019-09-26 | 2020-09-11 | 浙江大学 | 以羧基和吲哚基为功能基团的混合模式层析介质 |
US11932628B2 (en) | 2021-01-04 | 2024-03-19 | Regents Of The University Of Minnesota | Selective small molecule peptidomimetic melanocortin ligands |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5462927A (en) | 1985-04-30 | 1995-10-31 | The Administrators Of The Tulane Educational Fund | Peptides aiding nerve regeneration |
ATE109793T1 (de) | 1987-05-22 | 1994-08-15 | University Patents Inc | Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung. |
JP2795449B2 (ja) | 1987-09-24 | 1998-09-10 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 治療用ペプチド |
ZA908610B (en) | 1989-11-03 | 1991-08-28 | Univ Tulane | Peptides aiding nerve regeneration |
DE69212011T2 (de) | 1991-02-15 | 1997-01-09 | Takeda Chemical Industries Ltd | Endothelin Antagoniste |
ATE155486T1 (de) | 1991-08-13 | 1997-08-15 | Takeda Chemical Industries Ltd | Zyklische peptide und ihre verwendung |
ES2133295T3 (es) | 1991-11-19 | 1999-09-16 | Takeda Chemical Industries Ltd | Peptidos ciclicos y su uso. |
EP0547317A1 (fr) | 1991-12-19 | 1993-06-23 | Takeda Chemical Industries, Ltd. | Antagonistes d'endothéline |
DE9203901U1 (de) | 1992-03-24 | 1992-07-16 | Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen | Gestell zum Lagern von flächigen Werkstücken |
JP3553062B2 (ja) | 1992-07-27 | 2004-08-11 | ジ アドミニストレイターズ オブ ザ トュラン エデュケーショナル ファンド | ニューロメジンb受容体拮抗物質 |
US5569741A (en) | 1992-07-27 | 1996-10-29 | Biomeasure, Inc. | Cyclic octapeptide neuromedin B receptor antagonists |
AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
EP0714909A1 (fr) | 1994-12-01 | 1996-06-05 | Takeda Chemical Industries, Ltd. | Composition pour la prévention et le traitement de maladies de la circulation pulmonaire |
US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
US6054556A (en) * | 1995-04-10 | 2000-04-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Melanocortin receptor antagonists and agonists |
WO1996034012A1 (fr) | 1995-04-28 | 1996-10-31 | Takeda Chemical Industries, Ltd. | Antagonistes des recepteurs lh-rh pentapeptidiques cycliques |
US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
JP3784418B2 (ja) | 1996-06-11 | 2006-06-14 | ノバルティス アクチエンゲゼルシャフト | ソマトスタチン類似体およびラパマイシンの配合 |
JP3947228B2 (ja) | 1996-06-25 | 2007-07-18 | 株式会社日清製粉グループ本社 | 環状デプシペプチドおよびこれを有効成分とする医薬 |
EP0815870A3 (fr) | 1996-06-27 | 2000-05-03 | Takeda Chemical Industries, Ltd. | Composition de prophylaxie et de traitement d'infarction cérébrale |
US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
EP0946595A2 (fr) | 1996-12-17 | 1999-10-06 | Quadrant Holdings Cambridge Limited | Melanocortines |
SE9700620D0 (sv) * | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cykliska peptider med selektivitet för MSH-receptor subtyper |
GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
-
2000
- 2000-03-21 KR KR1020047019303A patent/KR100558131B1/ko not_active IP Right Cessation
- 2000-03-21 NZ NZ514141A patent/NZ514141A/xx unknown
- 2000-03-21 RU RU2001128890/04A patent/RU2213098C2/ru not_active IP Right Cessation
- 2000-03-21 PT PT00919500T patent/PT1165613E/pt unknown
- 2000-03-21 AU AU40179/00A patent/AU763510B2/en not_active Ceased
- 2000-03-21 KR KR10-2001-7012436A patent/KR100519201B1/ko not_active IP Right Cessation
- 2000-03-21 TR TR2001/02765T patent/TR200102765T2/xx unknown
- 2000-03-21 PL PL00350095A patent/PL350095A1/xx not_active Application Discontinuation
- 2000-03-21 DK DK00919500T patent/DK1165613T3/da active
- 2000-03-21 ES ES00919500T patent/ES2304345T3/es not_active Expired - Lifetime
- 2000-03-21 CN CNB008057540A patent/CN1249086C/zh not_active Expired - Fee Related
- 2000-03-21 AT AT00919500T patent/ATE393783T1/de not_active IP Right Cessation
- 2000-03-21 SK SK1308-2001A patent/SK13082001A3/sk unknown
- 2000-03-21 BR BR0009497-8A patent/BR0009497A/pt not_active IP Right Cessation
- 2000-03-21 DE DE60038734T patent/DE60038734T2/de not_active Expired - Fee Related
- 2000-03-21 JP JP2000608653A patent/JP2002542159A/ja active Pending
- 2000-03-21 CZ CZ20013407A patent/CZ20013407A3/cs unknown
- 2000-03-21 HU HU0202203A patent/HUP0202203A3/hu unknown
- 2000-03-21 ID IDW00200102111A patent/ID30262A/id unknown
- 2000-03-21 EP EP00919500A patent/EP1165613B1/fr not_active Expired - Lifetime
- 2000-03-21 CA CA002368431A patent/CA2368431C/fr not_active Expired - Fee Related
- 2000-03-21 WO PCT/US2000/007473 patent/WO2000058361A1/fr not_active Application Discontinuation
- 2000-03-21 MX MXPA01009881A patent/MXPA01009881A/es active IP Right Grant
- 2000-03-21 IL IL14540600A patent/IL145406A0/xx unknown
- 2000-03-27 MY MYPI20001220A patent/MY126585A/en unknown
- 2000-03-28 TW TW089105726A patent/TWI250990B/zh not_active IP Right Cessation
- 2000-03-28 CO CO00022068A patent/CO5170531A1/es not_active Application Discontinuation
- 2000-03-29 AR ARP000101405A patent/AR023201A1/es active IP Right Grant
- 2000-03-29 US US09/537,789 patent/US6613874B1/en not_active Expired - Fee Related
- 2000-03-29 PE PE2000000267A patent/PE20001641A1/es not_active Application Discontinuation
- 2000-06-26 SA SA00210192A patent/SA00210192B1/ar unknown
-
2001
- 2001-09-07 ZA ZA200107411A patent/ZA200107411B/xx unknown
- 2001-09-20 NO NO20014568A patent/NO20014568L/no not_active Application Discontinuation
- 2001-09-26 MA MA26340A patent/MA25403A1/fr unknown
-
2002
- 2002-06-24 HK HK02104687.8A patent/HK1044954B/zh not_active IP Right Cessation
-
2003
- 2003-07-02 US US10/612,104 patent/US6951916B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA25403A1 (fr) | Ligandes de recepteur de melanocortine | |
ATE253067T1 (de) | Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden | |
DE60026169D1 (de) | Selektive neurokinin-antagonisten | |
CY2010003I2 (el) | Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων | |
DE69926914D1 (de) | 1-heterozyklus-substituierte diarylaminen | |
ATE442087T1 (de) | Nähsystem | |
DK1189916T3 (da) | N-pyrazol A 2A-receptoragonister | |
DE50007721D1 (de) | Trageinrichtung | |
NO20023895D0 (no) | Anilin-avledete ligander for thyroid-reseptoren | |
NO20013954L (no) | Understöttelsesanordning | |
NO20013997D0 (no) | Reseptoranalyse | |
ATE305920T1 (de) | Bradykinin receptorantagoniste | |
NO20016053L (no) | IL-8 reseptor-antagonister | |
DK1070065T3 (da) | Azabicykliske 5-HT1 receptorligander | |
NO20016052L (no) | IL-8-reseptor-antagonister | |
MA25265A1 (fr) | Antagoniste du recepteur de vitronectime. | |
NO20014961D0 (no) | Integrin-reseptor-ligander | |
ATE352299T1 (de) | Il-8 rezeptorantagonist | |
NO20015774L (no) | IL-8 reseptorantagonister | |
NO20021295D0 (no) | Nikotinsyreacetylcholin-reseptor | |
NO20016102L (no) | IL-8 reseptorantagonister | |
NO20016065D0 (no) | IL-8-reseptor-antagonister | |
FI990869A0 (fi) | Olkatuki | |
NO994224D0 (no) | Underlagsmatte |